OB/GYN 1511 - OB/GYN Clinical Alert - Nov 01, 2011

Target Audience:

This activity is intended for the obstetrician and gynecologist.

Accreditation:

AHC Media is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation:

AHC Media designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty

Editor
Jeffrey T. Jensen, MD, MPH
Leon Speroff
Professor and Vice Chair for Research
Department of Obstetrics and Gynecology
Oregon Health and Science University
Portland

Peer Reviewer
Catherine Leclair, MD
Associate Professor
Department of OB/GYN
Oregon Health & Science University
Portland

Executive Editor
Leslie Coplin
AHC Media

Managing Editor
Neill Kimball
AHC Media

Associate Editors
John C. Hobbins, MD
Professor
Department of Obstetrics and Gynecology
University of Colorado Health Sciences Center
Denver

Robert L. Coleman, MD
Professor, University of Texas
M.D. Anderson Cancer Center
Houston, TX

Sarah L. Berga, MD
Professor and Chair
Department of Obstetrics and Gynecology
Vice President for Women's Health Services
Wake Forest Baptist Health
Winston-Salem, NC

Subjects:

  • Evaluating the Role of D&C vs Methotrexate in Etopic or Non-viable Intrauterine Pregnancy
  • Vaginal Progesterone
  • The Rapalogs: New Class of Therapy for Women with Endometrial Cancer
  • What the Reproductive Specialist Should Know about Detecting Thyroidal Conditions

Objectives:

  • Explain the latest data regarding diagnosis and treatment of various diseases affecting women
  • Discuss new data concerning prenatal care, neonatal health, and complications arising in pregnancy and the perinatal period
  • Discuss the advantages, disadvantages, and cost-effectiveness of new testing procedures in women?s health

Financial Disclosure:

OB/GYN Clinical Alert’s Editor, Jeffrey T. Jensen, MD, MPH, receives research support from, is a consultant to, and serves on the speakers bureau of Bayer Healthcare/Bayer Schering; he also receives research support from Merck Abbott Laboratories, Wyeth and Warner-Chilcott and is a consultant to Schering Plough. Peer Reviewer Catherine LeClair, MD, Executive Editor Leslie Coplin, Managing Editor Neill Kimball, Associate Editors John C. Hobbins, MD, and Sarah L. Berga, MD report no financial relationship to this field of study. Associate Editor Robert L. Coleman, MD, reports that he receives research funding from Novartis, which makes an mTOR inhibitor (everolimus).

Copyright 2011 AHC Media. All rights reserved.